People in the News

Oct 03, 2018

Jürgen Schulze, Alain Baverel

Sysmex Europe announced that Jürgen Schulze, its chairman, long-time president, and CEO, retired at the end of September. He will continue to support Sysmex as a member and vice-chairman of the MedTech Europe Executive Board, the firm said.

Schulze passed the baton to Alain Baverel, who has been transitioning into his role as president and CEO of Sysmex EMEA since April 2018. His role became official Oct. 1.

Baverel joined Sysmex in 2007 as managing director of the newly established affiliate Sysmex France.

Oct 03, 2018

Hayden Jeffreys

Hayden Jeffreys has become group commercial director at Premaitha Health. He joined the company from Cambridge Epigenetix, where he was chief operating officer. Before that, he was interim CEO at ERBA Diagnostics. Jeffreys holds an MSc in management studies from the University of Oxford and a BSc in genetics from Cardiff University.

Oct 02, 2018

Lawrence Culp

Former Danaher President and CEO Lawrence Culp was named the Chairman and CEO of GE on Oct. 1, effective immediately. He replaces John Flannery in the two positions. Culp has been a member of GE's board since April and led Danaher between 2000 and 2014. 

Sep 27, 2018

Joan Martin

Accelerate Diagnostics has announced that Joan Martin has resigned from his position as executive vice president and head of Europe, the Middle East, and Africa, and will be leaving the company for personal reasons. Lawrence Mehren, Accelerate's president and CEO, will oversee operations of the region on an interim basis until the vacancy is filled.

Sep 27, 2018

Laurie Goodman

ClearLight Diagnostics has appointed Laurie Goodman as CEO. Goodman had been serving as interim CEO since 2018 and chief scientific officer since 2015. She will continue serving as board manager and provide executive leadership for the firm moving forward. Prior to ClearLight, Goodman was senior director of scientific and medical affairs for Biodesix, and held senior level positions at Affymetrix, Monogram Biosciences, and Lynx Therapeutics.

Sep 25, 2018

Feng Deng

Feng Deng has joined the board of flow cytometry firm Cytek Biosciences. Deng is the founder of Northern Lights Ventures, which co-led Cytek's Series C financing round, whose completion was announced this week. Prior to Northern Lights, he cofounded NetScreen Technologies, which was later acquired by Juniper Networks for $4.2 billion.

Sep 24, 2018

John Kraeutler, David Phillips, Felicia Williams

John (Jack) Kraeutler has retired from his position as Meridian Bioscience's executive chairman of the board, effective Sept. 30, 2018. Kraeutler retired as CEO of the firm last year after 25 years in that position. Meridian has appointed David Phillips as the new chairman of the board, and has also elected Felicia Williams to the board of directors and to serve on the firm's audit committee, effective September 20, 2018. Williams previously served in financial positions at Macy's and Coca-Cola.

Sep 20, 2018

Hayden Jeffreys

Hayden Jeffreys has taken on a senior commercial role at Premaitha Health and will be appointed to the company's board in the near future. Most recently, he was the COO of Cambridge Epigenetix, and prior to that, interim CEO of ERBA Diagnostics.

Sep 18, 2018

Sam Tsimikas, Michael Davidson, and others

Boston Heart Diagnostics, a subsidiary of Eurofins Scientific, appointed five members to its scientific advisory board. They are Sam Tsimikas; Michael Davidson; Peter Reaven; Dennis Goodman; and H. Robert Superko. Tsimikas is a cardiologist at the University of California, San Diego specializing in lipoprotein. Davidson is a cardiologist at the University of Chicago with a specialty in omega-3 fatty acid metabolism and clinical use, while Reaven is at the University of Arizona where he researches insulin resistance and diabetes. Goodman specializes in integrative medicine at New York University, and Superko is a founder of Berkeley Heart Lab and a specialist in lipoprotein subfractionization.

Sep 14, 2018

Andy Richards

Owlstone Medical appointed Andy Richards to its board as a non-executive director. Richards, an entrepreneur and business angel, has an established track record in founding and scaling up innovative biotech and health technology companies in the UK, the firm said. His early career spans positions with Imperial Chemical Industries and PA Technology, and he was a founder and executive director of Chiroscience until its merger with Celltech in 1999. Since then, he founded, invested in, and helped to scale more than 25 innovative ventures including Vectura, Arakis, and Cambridge Biotechnology.

Sep 12, 2018

Bob Petrou

Bob Petrou has been named interim CFO and interim principal financial officer of NantHealth, replacing Paul Holt, whose resignation was effective Sept. 11. He will earn about $36,000 per month under a consulting agreement with the company, NantHealth disclosed in a regulatory filing. Petrou most recently was head of finance for the mobility solutions division of smartphone maker BlackBerry. 

Sep 11, 2018

Allan Brown, David Matthews

QuantuMDx appointed Allan Brown as chief operating officer and David Matthews as chief financial officer. Brown was previously COO and a board director at Genedrive where he oversaw the launch of the company's PCR-based platform, also called Genedrive, for diagnosing hepatitis C. He previously was at Qiagen and Tepnel Life Sciences. Matthews was previously CFO at Contextual Genomics and was part of the founding team at GenomeDx Biosciences. 

Sep 11, 2018

Chitra Nayak

Invitae's board of directors this week expanded the number of members on its board to six members and appointed Chitra Nayak as a member. Nayak most recently served as chief operating officer of the real estate technology company Comfy, which was acquired by Siemens in June. Prior to that, Nayak worked at Funding Circle, an online peer-to-peer lending marketplace, and the cloud computing company Nayak will stand for re-election on Invitae's board in 2021.
Sep 11, 2018

Katherine Atkinson

Epic Sciences has appointed Katherine Atkinson as its chief commercial officer, charging her with the development of the firm's global commercial strategy. Atkinson joins Epic with two decades of life science and healthcare experience. Most recently, she served as vice president of business development at Edico Genome, where she established a global channel network and managed strategic partnerships. Prior to Edico she worked for Illumina, overseeing numerous teams, including molecular biology/PCR sales, inside sales, Latin America, and most recently global channel partners. She has also held positions at Fisher Scientific, Thermo Fisher, and Beckman Coulter.

Sep 10, 2018

John Howard

MediXall Group has appointed John Howard as senior vice president of laboratory services. He will guide the company as it expands into the clinical laboratory testing market. MediXall expects to begin offering such testing before the end of the year, it said. 

Howard is negotiating with two "major" lab testing companies that would allow it to develop custom health screening lab test panels and profiles, which will include male- and female-specific panels, organ-specific panels, and cancer marker panels. It will also offer toxicology panels for urine drug testing and confirmation and different hormone panels. 

Howard started as a medical technology in clinical labs and later founded and built a clinical laboratory with more than 175 full-time employees. He also invented and founded PocketMD, which provides medical records on credit card-sized CD that can be carried in a wallet or purse.

Sep 10, 2018

Jack Challis

Cancer diagnostics shop Lucence Diagnostics appointed Jack Challis its healthcare analytics director. He will be based in San Francisco and will organize Lucence's streams of genomics data, as well as drive collaborations with research institutes and healthcare providers in the US. Challis cofounded CliniCast, which was acquired by Elekta in 2015. 

Sep 10, 2018

Edwin Hendrick

Biocept has appointed Edwin Hendrick as Senior Vice President and Chief Commercial Officer. Hendrick brings 25 years of sales and commercial leadership experience in the healthcare industry, with senior level commercial and operational positions at a variety of diagnostic and healthcare service companies. 

In his most recent position at GenomeDx, Hendrick developed the company's commercial strategy and launched its commercial offering. Prior to GenomeDx he served as executive vice president of sales and marketing at Plus Diagnostics. He also served as an executive with US Labs and led sales and marketing for Ventana Medical Systems after beginning his career in sales for Abbott Laboratories.

Sep 10, 2018

James Mullen

Thermo Fisher Scientific's board has elected James Mullen as a director, effective Nov. 8. He was appointed to the board's strategy and financing committee, and his term expires at the 2019 annual meeting. Mullen was CEO of Patheon until that firm's acquisition by Thermo Fisher in August 2017. Prior to Patheon, he was CEO and president of Biogen. 

Sep 07, 2018

Nikko Khazana and Mark Mozley

NantHealth has hired Nikko Khazana as senior VP for strategy and business development and Mark Mozley as SVP for global sales. Khazana had previously served as SVP of sales at CompanionDx Reference Lab. Mozley previously led sales efforts for life sciences and global strategic accounts at Clarivate Analytics. 

Sep 06, 2018

Steven Kafka

Steven Kafka has joined the board of directors of ArcherDX. He serves as a venture partner at Third Rock Ventures, and was previously the president and chief operating officer of Foundation Medicine, which is now owned by Roche. Before that, he was the COO and CFO of Aileron Therapeutics and VP of finance at Infinity Pharmaceuticals.

Sep 04, 2018

Katherine Atkinson

Epic Science has appointed Katherine Atkinson as chief commercial officer, tasked with the development of Epic's global commercial strategy.

Atkinson joins Epic with two decades of life science and healthcare experience, most recently as vice president of business development at Edico Genome. Prior to Edico, Atkinson worked for Illumina, where she oversaw a variety of sales teams. She has also held positions at Fisher Scientific, Thermo Fisher, and Beckman Coulter.

Aug 31, 2018

Nancy Stratton

Lab accreditation provider COLA announced the appointment of Nancy Stratton as chief executive officer.

Previously, Stratton was CEO of Clinical Pathology Laboratories, the largest division of Sonic Healthcare. She joined CPL in 1995 as a bench technologists, and served in various roles related to quality management, customer service, human resources, risk management, and regulatory and medical legal compliance. She was promoted to CEO of CPL in 2016.

Stratton takes over as CEO of COLA from Doug Beigel, who recently retired after more than 29 years with the organization. In her new role she will be responsible for driving the organization's continued growth and furthering its mission to promote excellence in laboratory medicine and patient care.

Aug 30, 2018

Rajesh Shrotriya, Andy Delao

Avant Diagnostics appointed Rajesh Shrotriya and Andy Delao to its board of directors.

Shrotriya, the former CEO and chairman of Spectrum Pharmaceuticals, has more than four decades of experience in medicine, first as a physician and then as a pharmaceutical industry executive. Under his leadership, Spectrum identified, developed, and commercialized several anti-cancer drugs. Prior to joining Spectrum, Shrotriya was executive vice president and chief scientific officer of SuperGen and chief medical officer of MGI Pharma.

Andy Delao is the senior director of marketing for Accuray, a radiation oncology technology company. He spent more than 8 years at GE Healthcare, where he held multiple roles assisting in developing and leading its Oncology Solutions Organization product marketing for the molecular imaging business.

Aug 30, 2018

Angeline McCabe

Veracyte has named Angeline McCabe as its vice president of investor relations and corporate communications, effective immediately. McCabe had been vice president of investor relations at WellCare Health Plans, and before that, she held investor relations and corporate communications positions at Health Net and Valeant Pharmaceuticals. 

Aug 29, 2018

Elaine Lyon

Elaine Lyon has joined the HudsonAlpha Institute for Biotechnology as director of the HudsonAlpha Clinical Services Lab. Lyon comes to HudsonAlpha from the University of Utah, where she served as medical director for molecular genetics, genomics, and pharmacogenetics at ARUP Laboratories. She also held a faculty position at the University of Utah School of Medicine. She holds a PhD in medical genetics from the University of Alabama at Birmingham, and completed a fellowship in clinical molecular genetics at the University of Utah. She has served as president of the Association for Molecular Pathology and is a member of the American College of Medical Genetics and Genomics.